Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) kicked off on Tuesday, up 10.06% from the previous trading day, before settling in for the closing price of $3.58. Over the past 52 weeks, AMLX has traded in a range of $1.58-$19.95.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 2300.59%. While this was happening, its average annual earnings per share was recorded -623.81%. With a float of $41.21 million, this company’s outstanding shares have now reached $67.71 million.
The extent of productivity of a business whose workforce counts for 384 workers is very important to gauge. In terms of profitability, gross margin is 53.5%, operating margin of -51.85%, and the pretax margin is -54.35%.
Amylyx Pharmaceuticals Inc (AMLX) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Amylyx Pharmaceuticals Inc is 39.47%, while institutional ownership is 61.64%. The most recent insider transaction that took place on Sep 30 ’24, was worth 59,429. In this transaction Co-Chief Executive Officer of this company sold 18,589 shares at a rate of $3.20, taking the stock ownership to the 3,120,569 shares. Before that another transaction happened on Sep 30 ’24, when Company’s Co-Chief Executive Officer sold 18,589 for $3.20, making the entire transaction worth $59,414. This insider now owns 3,220,569 shares in total.
Amylyx Pharmaceuticals Inc (AMLX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -623.81% per share during the next fiscal year.
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Trading Performance Indicators
Take a look at Amylyx Pharmaceuticals Inc’s (AMLX) current performance indicators. Last quarter, stock had a quick ratio of 4.66. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.90.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.45, a number that is poised to hit -0.70 in the next quarter and is forecasted to reach -1.75 in one year’s time.
Technical Analysis of Amylyx Pharmaceuticals Inc (AMLX)
The latest stats from [Amylyx Pharmaceuticals Inc, AMLX] show that its last 5-days average volume of 1.15 million was inferior to 2.04 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 93.24%. Additionally, its Average True Range was 0.21.
During the past 100 days, Amylyx Pharmaceuticals Inc’s (AMLX) raw stochastic average was set at 99.58%, which indicates a significant increase from 99.04% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 64.64% in the past 14 days, which was lower than the 71.85% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.62, while its 200-day Moving Average is $5.57. Now, the first resistance to watch is $4.06. This is followed by the second major resistance level at $4.18. The third major resistance level sits at $4.41. If the price goes on to break the first support level at $3.71, it is likely to go to the next support level at $3.48. The third support level lies at $3.36 if the price breaches the second support level.
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Key Stats
The company with the Market Capitalisation of 268.24 million has total of 68,006K Shares Outstanding. Its annual sales at the moment are 380,790 K in contrast with the sum of 49,270 K annual income. Company’s last quarter sales were recorded 88,640 K and last quarter income was -118,790 K.
